News | Proton Therapy | April 09, 2019

Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment

First preclinical results with ultra-high-dose proton therapy presented at AACR

Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment

April 9, 2019 — Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the Maryland Proton Treatment Center, presented publicly the first pre-clinical results of its research on ultra-high-dose rate cancer treatments with protons. Known as Flash therapy, it is a non-invasive therapy for cancer delivering high doses of radiation in ultra-high-speeds (less than 1 second) and represents the potential for a major breakthrough in the treatment of cancer. The preclinical Flash therapy results — presented at the American Association for Cancer Research (AACR) annual meeting, March 29-April 3 in Atlanta — showed reduced toxicity in healthy tissues and organs.

Conducted on a clinical device capable of translation to humans, the Flash therapy preclinical tests, compared to conventional proton treatments, displayed 25-30 percent less damage to lung tissue, resulting in less fibrosis of the lung, and an average of 35 percent reduction in skin dermatitis during treatment.

The FlashForward Consortium, comprised of 14 cancer centers, is focused on preclinical research, clinical implementation and advocacy efforts of Flash therapy. Working groups in the FlashForward Consortium are identifying preclinical study design for understanding this therapy, developing and sharing protocols that will enable a safe and quality clinical start for new users, and assist with regulatory and advocacy efforts.

“Partnering with Varian’s Global Translational Science team on the first proton Flash pre-clinical study, and being one of the founding members of the FlashForward Consortium, is a significant step in building a foundation of research and bridging the gap to patient benefits in this potentially game-changing therapy,” said William F. Regine, M.D., The Isadore & Fannie Foxman Chair and professor, Department of Radiation Oncology at the University of Maryland School of Medicine, and executive director of the Maryland Proton Treatment Center. The pre-clinical study was led by Zeljko Vujaskovic, M.D., Ph.D., professor of radiation oncology and director of the Division of Translational Radiation Services, and Lauren Jackson, Ph.D., associate professor of radiation oncology and deputy director of translational radiation sciences.

Read more about the data presented at AACR here.

For more information:

Related Content

Videos | Treatment Planning | August 21, 2019
This is an example of the Mirada DLCExpert deep learning software that automatically identifies organs, segments and
First Cancer Patient Treated With Accuray Radixact System With Synchrony Motion Tracking
News | Image Guided Radiation Therapy (IGRT) | August 21, 2019
Physicians at the Froedtert & the Medical College of Wisconsin (MCW) Clinical Cancer Center in Milwaukee have...
Videos | Patient Positioning Radiation Therapy | August 21, 2019
This is a quick demonstration of the Varian Identify image-guided patient positioning system at the...
Videos | Treatment Planning | August 21, 2019
This is a lung cancer tumor radiotherapy...
Videos | Computed Tomography (CT) | August 21, 2019
This is a quick walk around of a mobile 32-slice...
First GammaTile Therapy Case Completed in Arizona
News | Radiation Therapy | August 19, 2019
HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy, a...
Drug Accelerates Blood System's Recovery After Radiation, Chemotherapy

Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications

News | Radiation Therapy | August 16, 2019
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...